Emyria (ASX:EMD) share price falling on news of MDMA therapy trial

The Emyria Ltd (ASX: EMD) share price is falling after news from company of a psychedelic therapy program targeting PTSD.
The post Emyria (ASX:EMD) share price falling on news of MDMA therapy trial appeared first on The Motley Fool Australia. –

Bag of white pills spilled onto a blue surface

Shares in Emyria Ltd (ASX: EMD) are falling today after the company shared news of a psychedelic therapy program targeting post traumatic stress disorder (PTSD). At its intraday low, the Emyria share price has fallen by 5%.

At the time of writing, it has slightly recovered. Currently, the Emyria share price is down 3.85% – trading for 25 cents.

Let’s take a closer look at the drug development and clinical services company’s news.

Emyria’s MDMA-assisted therapy trial

Emyria – formerly known as Emerald Clinics Limited – is set to sponsor a clinical trial targeting treatment resistant PTSD with MDMA-assisted therapy.

The trial has been developed in partnership with Mind Medicine Australia, a charity working to help end suffering caused by mental illness by creating more treatment options

The trial, which is still pending ethics approval, will evaluate the safety, efficacy and cost benefits of MDMA-assisted psychotherapy.

While the company didn’t clarify how its trial will differ from others, it stated that most MDMA-assisted therapy involved 3 stages.

  • Preparation – in this stage the therapist and patient get to know one another and build trust
  • Administration and monitoring – the patient is given a dose of MDMA and supported by two therapists during a session which can last 6 to 8 hours
  • Integration – the next day, and at an average of 3 weekly intervals, the patient and therapist discuss the experience and its outcomes.

A cohort of therapists trained for the trial will graduate this month from Mind Medicine Australia’s training course. Emyria has a facility ready for the trial.

Currently, the two bodies are working to create an ethics protocol to receive ethics approval.

Prior research on MDMA-assisted therapy

According to Emyria’s release, between 5% and 10% of Australians are likely to develop PTSD during their lifetimes. The rate of Australian veterans who will experience PTSD is estimated to be closer to 20%.

The former chair of the Australian Defence Force Admiral Chris Barrie recently encouraged the Australian Government to consider the clinical use of specific psychedelics to help those recovering from trauma.

Emyria stated there is a body of evidence showing that in a controlled environment and supported by psychotherapy, ketamine, psilocybin, and MDMA can help with treatment-resistant mental illnesses.

It pointed to a study by the Multidisciplinary Association for Psychedelic Studies that found that 67% of those who received MDMA-assisted therapy for PTSD didn’t qualify for a PTSD diagnosis after three treatments.

Further, MDMA-assisted therapy for PTSD has been granted ‘Breakthrough Therapy’ status by the US Food and Drug Administration.

Commentary from management

Emyria’s managing director Dr. Michael Winlo commented on the company’s involvement in the trial:

At Emyria, our strength is in providing safe access to unregistered treatments while also generating clinical evidence. To date, we have cared for over 4,000 patients with major unmet needs (including more than 80 patients suffering with treatment resistant PTSD) and collected high-quality Real-World Evidence. Emyria’s clinical advisory, site network and data infrastructure is uniquely positioned to support safe and scalable psychedelic-assisted therapy, much like we have demonstrated and accomplished with cannabinoid medicines.

Emyria share price snapshot

The drop experienced by the Emyria share price as a result of today’s news is unlikely to bother most investors. That’s because it’s a tiny bit of turbulence when compared to the its recent take off.

Despite today’s fall, the Emyria share price is up 150% year to date. It’s also up 257% over the last 12 months.

The company has a market capitalisation of around $40 million, with approximately 254 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Emyria (ASX:EMD) share price falling on news of MDMA therapy trial appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!